UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000029663
Receipt No. R000033854
Scientific Title Prospective Cohort Study to investigate factors affecting Health Related Quality of Life and the Effectiveness of Symptoms Monitoring via Computer-based Health Evaluation System (CHES) in Patients with Metastatic solid cancers during chemotherapy
Date of disclosure of the study information 2017/12/01
Last modified on 2019/04/24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Prospective Cohort Study to investigate factors affecting Health Related Quality of Life and the Effectiveness of Symptoms Monitoring via Computer-based Health Evaluation System (CHES) in Patients with Metastatic solid cancers during chemotherapy
Acronym PROMISE-KOBE Study
Scientific Title Prospective Cohort Study to investigate factors affecting Health Related Quality of Life and the Effectiveness of Symptoms Monitoring via Computer-based Health Evaluation System (CHES) in Patients with Metastatic solid cancers during chemotherapy
Scientific Title:Acronym PROMISE-KOBE Study
Region
Japan

Condition
Condition Patients with metastatic solid cancer (gastric cancer, colorectal cancer and breast cancer) scheduled for first line chemotherapy (including molecular targeted drug and immune checkpoint inhibitor)
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 1)To clarify factors that decrease health related quality of life (HRQOL) of metastatic solid cancer patients undergoing chemotherapy at Kobe City Medical Center General Hospital.

2)To evaluate the effectiveness of patient's symptom monitoring via Computer-based Health Evaluation System
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes EQ-5D-5L
Key secondary outcomes Global Health Status scale in EORTC QLQ-C30
EORTC QLQ-C30(five functional scales and three multi-item symptom scales)
EORTC QLQ-CIPN20
Overall survival from the registration date
Association between clinicopatholigical factors and HRQOL
Association between sociodemographic factors and HRQOL
Association between visiting emergency room and HRQOL
Association between visiting palliative care unit and HRQOL
Association between symptom monitoring via Patient Portal Site and HRQOL

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Patients with metastatic solid cancer (gastric cancer, colorectal cancer, breast cancer)
2) Patients who are scheduled for first-line chemotherapy (including molecular targeted drug and immune checkpoint inhibitor)
3) Patients who are going to do chemotherapy at the outpatient chemotherapy unit
4) Patient with ECOG Performance Status of 0 to 2.
5) Patients who are expected to have a prognosis of six months or more
6) Written informed consent, with the understanding that the patient may withdraw consent at any time without prejudice

Key exclusion criteria 1) Patients with serious complications
2) Patients who have clinically problematic mental illness
3) Patients judged inappropriate for enrolment by physician
Target sample size 115

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yuichiro Kikawa
Organization Kobe City Medical Center General Hospital
Division name Department of Breast Surgery
Zip code
Address 2-2-1, Minatojimaminamimachi, Chuo-ku, Kobe-city, Hyogo, 650-0047, Japan
TEL +81-78-302-4321
Email u-1ro@kcho.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yuichiro Kikawa
Organization Kobe City Medical Center General Hospital
Division name Department of Breast Surgery
Zip code
Address 2-2-1, Minatojimaminamimachi, Chuo-ku, Kobe-city, Hyogo, 650-0047, Japan
TEL +81-78-302-4321
Homepage URL
Email u-1ro@kcho.jp

Sponsor
Institute Kobe City Medical Center General Hospital
Institute
Department

Funding Source
Organization Kobe City Medical Center General Hospital
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2017 Year 12 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2017 Year 10 Month 30 Day
Date of IRB
2017 Year 11 Month 01 Day
Anticipated trial start date
2018 Year 01 Month 01 Day
Last follow-up date
2021 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information The baseline HRQOL survey will be conducted during the period of registration and first chemotherapy. Two more evaluations will be performed after 12 weeks and 24 weeks from the treatment start date.
Furthermore, the following items will be evaluated;
sex, highest level of education, employment status, martial status, living situation, caner site, performance status, comorbidity, visiting history of emergency room and consultation history of palliative care unit

Management information
Registered date
2017 Year 10 Month 22 Day
Last modified on
2019 Year 04 Month 24 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033854

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.